GYRE - Gyre Therapeutics Inc - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

1.276B

Cash

37.35M

Avg Qtr Burn

N/A

Short % of Float

1.86%

Insider Ownership

81.73%

Institutional Own.

0.99%

Qtr Updated

03/31/24

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Avatrombopag Details Thrombocytopenia , Chronic liver disease	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
F351 (Hydronidone) Details Chronic hepatitis B, Liver fibrosis	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
F351 (Hydronidone) Details Non-alcoholic steatohepatitis , Liver fibrosis	Phase 2a Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.